Search Clinical Trials in the European Union
Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1621-1640 of 3,900 trials
Facioscapulohumeral Muscular Dystrophy1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNeurology
Metastatic Colorectal Cancer>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology
Clear Cell Endometrial CarcinomaNon-Small Cell Lung CancerSmall Cell Lung Cancer>2 yearsSafety phase (I)Oncology
Von Willebrand's Factor Deficiency>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementHematologyPediatrics
Metastatic Colorectal CancerEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyOncology
COVID-19Efficacy phase (II)Confirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPediatrics
Ulcerative Colitis3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics
Aortic Valve Disease>2 yearsMonitoring phase (IV)6-10 visitsStandard MedicinesCardiologyOtolaryngology
Localized Prostate Cancer>2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesOncology
Chronic Lymphocytic Leukemia (CLL)>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology
Non-Small Cell Lung CancerEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPulmonology
Early Alzheimer's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology
Acute Lymphoblastic Leukemia6-12 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementHematologyPediatrics
Chronic Rhinosinusitis with Nasal PolypsChronic Rhinosinusitis without Nasal Polyps>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesAllergologyOtolaryngology
HypogonadismType 2 Diabetes Mellitus (T2DM)Prediabetes>2 yearsMonitoring phase (IV)Post-Trial Drug AccessInvestigational MedicinesDiabetologyEndocrinologyInternal Medicine